Searchable abstracts of presentations at key conferences in endocrinology

ea0028p64 | Clinical practice/governance and case reports | SFEBES2012

Danazol falsely elevates oestradiol levels in a woman with ovarian failure

Devine K , Freel E , Perry C

A 29 year old woman with multiply-relapsed Hodgkin’s lymphoma became amenorrhoeic with vasomotor menopausal symptoms following multiple cycles of chemotherapy. Subsequent biochemistry confirmed primary gonadal failure (LH 30.7 U/L, FSH 49.9 U/L, oestradiol <70 pmol/L). Following allogeneic bone marrow transplantation she developed severe haemolytic anaemia and thrombocytopenia. This was resistant to standard therapies, including methylprednisolone, mycophenolate mofet...

ea0048cp15 | Poster Presentations | SFEEU2017

Pituitary apoplexy presenting with hypopituitarism and a generalised tonic clonic seizure

Gandhi S E , Kueh C J L , Perry C

Case history: A 28 year old male presented following his first generalised tonic clonic seizure in the context of a headache with mild photophobia, nausea and vomiting. He was haemodynamically stable, euvolaemic and had no focal neurological deficit, but was mildly disoriented. He had reported cannabis and MDMA use 8 days prior to his presentation. The patient was profoundly hyponatraemic with a serum sodium of 108.Investigations: Serum osmolality was 22...

ea0036P69 | (1) | BSPED2014

Bone mass and body composition in adolescents with childhood onset GH deficiency

Ahmid M , Shepherd S , Perry C G , Mason A , Ahmed S F , Shaikh M G

Background: Childhood-onset GH deficiency (CO-GHD) is perceived to be a cause of low bone density and osteoporosis in adulthood. Data on bone mass and body composition of GH-treated adolescents with CO-GHD at final height are inconsistent.Aims: To compare size/height corrected parameters of bone mass and body composition in adolescents with CO-GHD at final height.Method: Review of CO-GHD treated patients at final height between 200...

ea0030p54 | (1) | BSPED2012

Management of childhood-onset GH deficiency in young adulthood

Ahmid Mahjouba , Perry C G , Donaldson M , Ahmed S F , Shaikh M G

Background: GH therapy in adolescents with childhood onset GH deficiency (CO-GHD) is often necessary to prevent adult GHD syndrome and requires a re-evaluation of the GH axis on attainment of final height. Not all individuals with CO-GHD remain GH deficient and re-evaluation is required to confirm or refute adult GHD.Aim: Review the care received by young adults diagnosed with CO-GHD.Design: Retrospective review of young adults wit...

ea0027p78 | (1) | BSPED2011

Audit of Endocrine Adolescent Transition Clinic, RHSC Glasgow, 2008–2010

Mason Avril , Ahmed S F , Donaldson M D , McNeill E , Campbell V , Perry C , Shaikh M G

Introduction: A multi-disciplinary endocrine Adolescent Transition Clinic (ATC), with key professionals from paediatric and adult services, was instituted at the Royal Hospital for Sick Children, Glasgow, in October 2008 serving young people in the West of Scotland. A good transition should improve clinic attendance, health outcomes and quality of life into adulthood.Aim: To systematically review the success of ATC in engaging young people following thei...

ea0077ec1.3 | Clinical Endocrinology Trust Best Abstract Clinical | SFEBES2021

Phase 3 and extension study of modified-release hydrocortisone in the treatment of congenital adrenal hyperplasia

Merke Deborah P , Mallappa Ashwini , Arlt Wiebke , De La Perriere Aude Brac , Hirschberg Angelica Linden , Juul Anders , Newell-Price John D C , Perry Colin Graham , Prete Alessandro , Rees Aled , Reisch Nicole , Stikkelbroeck Monica , Touraine Philippe A , Lewis Alexander , Maltby Kerry , Treasure Peter , Porter John , Ross Richard John M

Background: Patients with congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency have poor health outcomes. We compared disease control in CAH adults treated with modified release hydrocortisone (MRHC, Chronocort®, Diurnal Ltd) versus standard glucocorticoid (GC).Methods: 6-month, Phase 3 study in 122 patients randomised to either MRHC twice daily or standard GC followed by safety extension study on MRHC. Patients had 24-hr 17...